While the weight loss results were impressive across the group, the cost and side effects remain important barriers for ...

Eli Lilly plans to turn India into a growth market by addressing its diabetes and obesity challenges with its new treatment, ...

Eli Lilly is exploring partnerships with Indian pharma firms to market its anti-diabetes and weight loss drug Mounjaro, ...

I've been following the developments around Ozempic and GLP-1 drugs with some interest for a while, and last week Eli Lilly launched its variant, Mounjaro, in India. Remember, India has the highest ...

What is obesity? Here's what you need to know about the disease expected to impact 50% of adults worldwide by 2050.

Indian markets posted their seventh straight session of gains, the longest winning streak since September 2024. The NSE Nifty 50 ended 10.30 points higher at 23,668.65, while the BSE Sensex closed ...

Unlike the US, Europe or other developed markets, Mounjaro will have to be purchased out-of-pocket in India, as obesity is ...

Trump hinted that the US will impose a 25%+ tariff on pharmaceuticals after giving US companies time to build more ...

Mounjaro (Tirzepatide), a groundbreaking GLP-1 receptor agonist targeting GIP receptors, is now available in India for ...

With Eli Lilly’s Mounjaro entering India, the weight-loss drug race is on. But with steep prices and generics on the way, how ...

Eli Lilly launches Mounjaro in India, targeting the $150B weight-loss market. The GLP-1 drug offers diabetes control & major ...

Zerodha’s Nithin Kamath sparks debate on Ozempic, Mounjaro & their game-changing impact on obesity, addiction & industries. Is India ready for this shift?